Transform Your Myeloma Strategy with
Fractional Advisory Boards
All the value of traditional advisory boards, at a fraction of the cost and time
KOLs Past events have included:
Sagar Lonial, Irene Ghobrial,
Ola Landgren, Faith Davies, Maria V Mateos,
Hartmut Goldschmidt, Francesca Gay,
Xavier Leleu and many others.
Insights Executive summary, key insights and
takeaways with a full transcript delivered
within 72 hours.
Less Cost The same high-quality
deliverables as traditional advisory boards
at a fraction of the cost and complexity.
• Access elite myeloma KOLs for strategic, actionable insights that drive results
• Private 2-2.5 hour sessions, scheduled around major conferences like IMS and ASH
• No logistics or contracting hassles, we handle everything from planning to execution
• High-quality deliverables (summary, transcript, insights) included
MYBoard - September 16th at IMS Conference
What is MYBoard?
MYBoard gives you direct access to the world’s top myeloma minds, faster, smarter, and at a fraction of the cost of traditional advisory boards.
Engage in sharp, high-impact discussions with KOLs like Drs. Lonial, Ghobrial, Landgren, and Mateos. Each session is fully customized, expertly moderated, and designed to deliver strategic, actionable insights.
You’ll receive a complete executive summary, transcript, and prioritized recommendations, delivered within 72 hours.
Held alongside major conferences like IMS and ASH, MYBoard sessions run 2-2.5 hours and are fully managed from start to finish. All you do is show up.
Top pharma teams are already using MYBOARD to:
Slots are limited. Ready to see if it's a fit?
Traditional Advisory Boards Are Broken
Top-20 Pharma Companies Choose MYBoard
Proven results that speak for themselves
$61,000+
Saved per advisory vs. traditional formats
3-4 Weeks
Reduced setup time from 4–6 months
100%
Maintained confidentiality and compliance
3 Days
Delivered actionable insights post-session
Elite KOLs
Access to top experts from ASH, IMS, and beyond
The Advantages of Choosing MYBoard
Engage with Leading KOLs
Our advisory boards are co-chaired by renowned myeloma specialists. Participants include leading researchers and clinicians from top institutions worldwide.
Tailored to Your Needs
Each advisory board is driven by the specific needs and objectives of participating organizations, ensuring relevant insights and actionable outcomes.
Cost Efficient
Our structured advisory boards are designed to be both time and cost-efficient, providing high-value insights without the high costs of
traditional events.
Convenient and Flexible
Our structured 2-hour time slots provide an easy way to access high-level expertise without the hassle of organizing separate events.
Post-Event Deliverables
We provide detailed executive summaries, key takeaways and actionable recommendations within 72 hours of your event.
All Logistics Included
From expert selection to venue booking, communications, and strategic planning, we manage every aspect of your
advisory event.
Enhanced with Value-added Features
Precision Thought Leader Recruitment
We secure the best-fit KOLs based on your goals and regional preferences.
Rapid Insights Report
Receive a concise executive summary and full report with strategic takeaways and clear, actionable insights, delivered within 72 hours post-session
Data Compass Myeloma Conference Reports
Data Compass identifies the signal in thousands of abstracts, highlighting those that challenge standards of care, accelerate innovation, and change practice.
Join us at Major Industry Events
Connect with our experts at the most important myeloma conferences of 2025
International Myeloma Society (IMS) Meeting
Sept. 17 - 20, 2025 | Toronto, Canada
Lymphoma, Leukemia & Myeloma Congress
Oct. 14-17, 2025 | New York City
American Society of Hematology
Dec. 6-9, 2025 | Chicago, IL
Frequently Asked Questions
Get answers to common questions about MYBOARD
Is this a shared session with other companies?
No. Each MYBOARD session is private and customized to your company.
Will I know which KOLs are attending?
Yes. You will receive a curated KOL list in advance based on your goals.
Can this be applied to other tumor types or therapeutic areas?
Our current focus is multiple myeloma, but expansion is possible—ask us.
How do you handle compliance?
We manage all documentation, NDAs, and regulatory reporting per global best practices.
What Our Clients Say
Trusted by leading pharmaceutical and biotech companies worldwide
"MYBoard transformed our approach to expert engagement. The quality of insights and efficiency of the process exceeded our expectations."
"The cost-effectiveness and quality of MYBoard advisory sessions have made it an essential part of our strategic planning process."